This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cellceutix Cancer Drug, Kevetrin™, Shows Increased Levels Of P21; Biomarker For Cancer Trials

BEVERLY, Mass., March 31, 2011 /PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX) , a biopharmaceutical company focused on discovering and developing small molecule drugs to treat severe medical conditions including drug-resistant cancers, is pleased to announce that additional research has been concluded on Kevetrin™, the Company's flagship cancer compound.  Kevetrin was shown to increase levels of p21, a key protein responsible for cell cycle arrest, in the lymphocytes of mice.  Cellceutix will be incorporating the p21 assay into its Investigational New Drug application scheduled to be filed with the Food and Drug Administration in approximately six weeks ( May 2011).  If the data are duplicated in human studies, p21 as a biomarker will be another major step forward in cancer research for Kevetrin™, which has already been shown to be a non-genotoxic drug that reactivates p53; a major development of its own.

Dr. Krishna Menon, Chief Scientific Officer for Cellceutix, commented, "There has been a big movement in oncology research to establish new biomarkers as they are an earlier measure of activity in the body's cells.  p21 has been proven to play a critical role in cell cycle arrest leading to cell death.  No one has been able to validate it as a biomarker, to the best of our knowledge, so this will be a major event not only for Cellceutix, but for the cancer clinical trials."  Dr. Menon continued, "Increased levels of p21 are not only a predictor of cell death, but a benchmark in judging effectiveness of Kevetrin™.  Our pre-clinical research on p21 has met its endpoints and we are optimistic that the upcoming human trials will yield similar results."

About Cellceutix

Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at www.cellceutix.com.

Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs